Reported about 15 hours ago
Aflac Inc., a supplemental health and life insurance provider, has seen its stock underperform compared to the broader market, gaining only 2.6% in the past year. Following better-than-expected Q2 results, the stock received a consensus 'Hold' rating from 16 analysts, with price targets ranging from a Street-high of $124, indicating a potential 19.8% upside, to a lowered target of $111 from UBS. Analysts expect an adjusted EPS of $6.81 for fiscal 2025, down 5.6% year-over-year.
Source: YAHOO